
Liquidia Technologies ( ($LQDA) ) just unveiled an update. Liquidia Corporation, a Delaware corporation, had its board appoint Russell Schundler as chief strategy officer and general counsel on November 12,
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| LQDA | Liquidia Technologies | 56.40 | 26.93 | 91.40% |
| Name | Price | % Change | |
|---|---|---|---|
| $56.40 | +91.40% |

Liquidia Technologies ( ($LQDA) ) just unveiled an update. Liquidia Corporation, a Delaware corporation, had its board appoint Russell Schundler as chief strategy officer and general counsel on November 12,

H.C. Wainwright analyst Matthew Caufield assumed coverage of Liquidia (LQDA) with a Buy rating and $76 price target The company’s October settlement with United Therapeutics (UTHR) “opens a new chapter

Bullish option flow detected in Liquidia (LQDA) Technologies with 7,639 calls trading, 1.3x expected, and implied vol increasing over 4 points to 73.74%. 11/13 weekly 60 calls and 11/13 weekly

The major averages were higher near noon, led by a big rebound in the Nasdaq as a better-than-expected quarterly report from CoreWeave helped ease concerns around the sustainability of AI

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by

Raymond James analyst Ryan Deschner upgraded Liquidia (LQDA) to Strong Buy from Outperform with a price target of $77, up from $53. Liquidia’s Yutrepia launch continues to exceed expectations, with

Raymond James analyst Ryan Deschner upgraded Liquidia (LQDA) to Strong Buy from Outperform with a price target of $77, up from $53. Published first on TheFly – the ultimate source

BofA raised the firm’s price target on Liquidia (LQDA) to $54 from $42 and keeps a Neutral rating on the shares after the company reported Q3 Yutrepia sales in line

Wells Fargo raised the firm’s price target on Liquidia (LQDA) to $40 from $33 and keeps an Equal Weight rating on the shares. The firm found commentary on October demand

Liquidia Technologies (LQDA) has disclosed a new risk, in the Debt & Financing category. Liquidia Technologies faces material financing risk if YUTREPIA revenues fail to cover commercialization, clinical development and
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 18, 2027TBA | $5.11B | $1.12 | $231.52M | 0.83 | -54.32 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.